Histiocytic Sarcoma in Dogs: A Guide for Families and Breeders
Health and Genetics
Histiocytic sarcoma is the cancer that sits behind the Bernese Mountain Dog's reputation for a short life. Here is what it actually is, why crossbreeding does not make it disappear, and the screening and pairing goals we hold because of it.
By James G. Stokes, MBA · November 2026 · Written for families and breeders
The short answer
Histiocytic sarcoma is an aggressive cancer of the immune system's histiocytes, the cells that patrol tissue and present threats to the rest of the immune system. It is uncommon across dogs generally, but it clusters strongly in a few breeds, most notably the Flat-Coated Retriever and the Bernese Mountain Dog. It is polygenic, meaning many genes each contribute a small amount of risk, so there is no single test that clears a dog of it. At Stokeshire Designer Doodles we do not claim that crossbreeding removes this risk. We screen the parents, we favor outcrossed pairings with low projected inbreeding, we take joint health seriously because joint disease appears to be a genuine risk factor, and we track what families report back to us.
Most families who come to us for a Bernedoodle or an Australian Mountain Dog have read something about Bernese Mountain Dogs and cancer. Usually it is a number, often an alarming one, and usually with no study attached. Then they read that crossbreeding fixes it. Both of those things deserve a more careful answer than the internet generally gives, and the honest version is more useful than the reassuring one.
This cancer is also personal to how we plan litters. Bernese lineage is part of what makes a Bernedoodle a Bernedoodle, and part of what makes the Australian Mountain Dog what it is. If we are going to build a program on those lines, we owe families a clear account of what comes with them and what we do about it.
What is histiocytic sarcoma in dogs?
Histiocytes are immune cells. Some of them, the dendritic cells, act as scouts: they capture material from tissue and present it to the immune system so a response can be organized. Others, the macrophages, do the clearing work, engulfing debris, worn-out cells, and pathogens. Both types live throughout the body, which is part of why this cancer can appear in so many different places.1,2
Histiocytic sarcoma is what happens when one of these cell lines turns malignant. Because the parent cell is mobile and present nearly everywhere, the disease tends to behave aggressively and to spread, and the form it takes depends on which histiocyte it came from and where it started.1,3
The cell a tumor comes from predicts how it behaves. Dendritic cell tumors account for most localized and disseminated cases. The hemophagocytic form arises from macrophages in the spleen and bone marrow and carries the poorest outlook.
The four ways it shows up
Families often hear "histiocytic sarcoma" as one disease. In practice veterinarians sort it into forms that look quite different in the exam room.
Tap a form to see what it looks like in practice.
LocalizedSubcutaneous tissue or deep fascia, commonly on a limb
What an owner may notice
A firm mass under the skin, often not especially painful. Because it can be painless and slow to change, it is easy to watch rather than act on.
PeriarticularThe soft tissue around a major joint: elbow, stifle, shoulder
What an owner may notice
Progressive limping, swelling around the joint, reluctance to use the leg. This is the form with a known and partly modifiable risk factor, covered further down.
DisseminatedSeveral organ systems at once
What an owner may notice
Appetite loss, weight loss, lethargy, fever, pale gums, labored breathing, a swollen abdomen. Signs tend to build over days rather than weeks.
Central nervous systemBrain, meninges, or spinal cord
What an owner may notice
Seizures are the most common first sign, along with rapidly changing neurologic behavior such as altered balance, vision, or temperament.
Two points matter for families. First, localized disease is not reliably contained: it tends to spread to regional lymph nodes and then onward, which is why veterinarians stage it carefully rather than simply removing the lump.1,4 Second, the periarticular form is the one with a known and partly modifiable risk factor, which we come back to below.
Which dogs carry elevated risk?
This cancer is uncommon in dogs as a whole, and that is the context for everything that follows. What makes it striking is how unevenly it is distributed. A study of 73 affected dogs in Japan calculated how over-represented each breed was compared with the hospital population, and the spread is wide.5
Figures from a Japanese referral population (Fujiwara-Igarashi and colleagues, 2014). Rottweilers are also consistently over-represented in case series, and separate work has found Pembroke Welsh Corgis and Shetland Sheepdogs predisposed specifically to the central nervous system form. The Corgi finding has not been as evident outside Japan, which is a reminder that these figures describe the population studied rather than every population.
Research in Bernese Mountain Dogs, Flat-Coated Retrievers, and Golden Retrievers has mapped shared inherited risk to several chromosomes, including a region near the CDKN2A and CDKN2B tumor suppressor genes. Those same regions appear to raise risk for other cancers as well, which is one reason breeding away from a single disease is harder than it sounds.6,7 Published studies from Denmark, the Netherlands, and Switzerland report cancer as a major cause of death in the Bernese Mountain Dog, and histiocytic sarcoma as a significant contributor within that.8,9,10
Why crossbreeding does not erase this risk
This is the part that gets misrepresented most often, including by people selling puppies.
Crossing distinct breed lines can increase genetic diversity and may reduce the likelihood that some recessive inherited conditions are expressed. It does not eliminate genetic disease or the health considerations present in the parent breeds.
The reason that distinction matters here is mechanical. A simple recessive disease needs two copies of one variant to show up. Cross two unrelated lines and the odds of a puppy receiving two copies of the same rare variant drop. Histiocytic sarcoma does not work that way. Current evidence describes it as polygenic: risk accumulates from many variants across several chromosomes, each adding a little.6,7 Halving the dose of an additive risk load is not the same as removing it.
Illustrative, not a prediction for any pairing. The point is the difference in kind: one gene can be bred around with a test, while an additive risk load carried across many genes can be reduced but not cleared.
Hybrid vigor is real as a statement about genetic diversity. It is not a promise about cancer. We use the term, and we explain what it does and does not cover.
We keep that distinction in our own copy. You can read how we describe genetic diversity, and what we will not claim because of it, on our Bernedoodle health and lifespan page. Every breed did start as a cross, and outcrossing is the foundation of our program. It is still not a shield against a polygenic cancer.
There is one more trap worth naming. Both the Bernese Mountain Dog and the Poodle populations carry variants for degenerative myelopathy and for von Willebrand disease type 1. Where both parent breeds carry the same variant, crossing them does not help, and two carriers can produce an affected puppy. That is an argument for testing parents, not for assuming a cross is covered. We write about one of those in detail on degenerative myelopathy and SOD1B in Bernese lines.
The risk factor that appears to be modifiable: joints
Most of what drives this disease is inherited and not currently something a breeder can test away. There is one exception that research keeps pointing at, and it is the most practically useful finding in this whole topic.
Dutch researchers looking at Bernese Mountain Dogs found that a dog with previous disease in a joint was substantially more likely to develop periarticular histiocytic sarcoma in that same joint.11 A later case-controlled study extended the finding beyond Bernese Mountain Dogs, reporting markedly higher odds of prior joint disease in the tumor-affected joint, with cranial cruciate ligament rupture the most common prior problem in stifle cases.12 A separate risk-factor study in Bernese Mountain Dogs found that dogs diagnosed with orthopedic conditions were more likely to develop histiocytic sarcoma, while dogs with a long history of prescription anti-inflammatory and joint-support medication were at lower risk.13
Taken together, these findings suggest an association between chronic local inflammation in a joint and the development of this cancer. The authors of that work describe it as an association rather than a proven cause, and it has not been established in doodles or in crossbred dogs.
What this does not mean
It does not mean anti-inflammatory medication should be given to a healthy dog to prevent cancer. That study observed dogs already being treated for joint problems, and these medications carry their own risks. Any decision about long-term medication belongs with your veterinarian, who knows your dog.
What it does mean, for us, is that orthopedic screening and joint protection are not only about mobility and comfort. They may also matter for this. That is why we take hip and elbow evaluation seriously in our breeding stock, and why our guidance to families during the growth window favors self-paced, lower-impact activity over forced distance running and repeated high-impact jumping. Skeletal maturity varies by dog and by size, so families should work with their veterinarian before beginning sustained running or other high-impact activity. Keeping a dog lean for life is part of the same picture.
Our goals as a program
We would rather tell you what we measure than make a claim about outcomes we cannot control. Here is the honest version, including the gaps.
Tap any item to see what it does and does not cover.
Genetic testing on every breeding dog before a pairing is plannedThrough Embark. Families receive both parents' results.
What it tells you
Known single-gene risks the panel covers, coat genetics, and breed composition for that dog.
What it does not tell you
It does not report a histiocytic sarcoma risk score. No panel in our program does.
Both degenerative myelopathy tests, SOD1A and SOD1BOn our Bernese-lineage breeding dogs
What it tells you
Whether a pairing could produce an affected puppy for a variant that both parent breeds carry.
What it does not tell you
Nothing about cancer risk.
Orthopedic evaluationOFA-recorded hip and elbow evaluations where completed, and PennHIP hip evaluations where completed
What it tells you
Structural joint quality in the parents, which is the area where the evidence above is most relevant.
What it does not tell you
It cannot predict any individual puppy's joints, or a future joint injury.
Cardiac and ophthalmologic examinationsAs appropriate to the lineage
What it tells you
Conditions relevant to the parent breeds involved.
What it does not tell you
Nothing about cancer risk.
Outcrossed pairings with a projected coefficient of inbreedingOur goal is every pairing at 15 percent or under, and to publish the projected figure, if known, on each litter page
What it tells you
How closely related a pairing is, which is the measurable difference between an outcross program and line breeding.
What it does not tell you
A low figure reduces the chance of doubling up on recessive variants. It is not a cancer claim.
Growth-window guidance, and outcome trackingOn exercise, body condition, and nutrition, and we ask families to tell us about diagnoses
What it tells you
What we can influence after a puppy goes home, and what is actually happening across our lines over time.
What it does not tell you
Reported data is incomplete by nature, since it depends on families telling us.
Two things we will not say. We will not tell you that a Bernedoodle, an Australian Mountain Dog, or a Golden Mountain Doodle has a reduced cancer risk because it is a crossbreed. Breed-specific cancer incidence has not been established for these crosses, and claiming a benefit nobody has measured would be marketing rather than information. We also will not tell you that screening removes this risk. No health-testing program can eliminate every genetic or developmental risk. These screenings are used to inform pairing decisions and reduce avoidable inherited risk wherever current testing and pedigree information allow.
You can see the dogs behind our pairings on our breeding dogs page, and the terms of what we stand behind on our health guarantee page.
When to call your veterinarian
This cancer moves quickly, and early assessment matters. None of these signs means histiocytic sarcoma, and all of them are worth a call.
- A limp that is getting worse rather than better, especially with swelling around the elbow or knee
- A firm mass under the skin, particularly on a limb, whether or not it seems painful
- Appetite loss or weight loss with low energy over days rather than weeks
- Pale gums, labored breathing, or a visibly swollen abdomen
- A first seizure, or sudden changes in balance, vision, or behavior
- Persistent fever with no obvious cause
Ask for staging rather than removal alone if a mass is found, because this disease can spread from a site that looks local. A sample read by a pathologist is what distinguishes it from other tumors, and that distinction changes treatment.
What is being researched
Treatment today generally combines surgery for genuinely localized disease with chemotherapy, and outcomes vary widely by form and by how early it is found. That is a conversation for a veterinary oncologist rather than a web page.
The research picture is more encouraging than it was. Sequencing work has found activating mutations in the gene PTPN11 in a substantial share of canine cases, which places this cancer within signaling pathways that targeted drugs already address in other diseases.14 Transcriptome work has flagged additional candidate targets.14 Trials of a targeted MEK inhibitor in dogs with histiocytic sarcoma have moved beyond initial safety work. For breeders, polygenic risk-index testing has been developed for purebred Bernese Mountain Dogs, and the club that administers it is careful to describe it as a risk tool rather than a diagnostic one.15
There is also a reason this matters past dogs. Histiocytic sarcoma in people is rare enough to be very hard to study, and the canine disease is studied partly as a model for it. Work funded to help dogs is also work that may help people.
Common questions
Tap a question to open it.
Can a test tell me whether my puppy will get histiocytic sarcoma?
No. The disease is polygenic, meaning risk comes from many genes each adding a small amount, so no single test clears a dog. A risk-index test exists for purebred Bernese Mountain Dogs and reports a probability band rather than a yes or no, and the club that administers it notes that low-risk dogs can still develop the disease.
Does a Bernedoodle have a lower risk than a Bernese Mountain Dog?
Nobody has measured it. Crossing distinct lines increases genetic diversity and reduces the chance of doubling up on recessive variants, but this cancer is additive across many genes, so the risk is reduced in principle rather than removed. Breed-specific cancer incidence has not been established for Bernedoodles, and we do not claim a figure.
At what age does this usually appear?
Published case series generally report middle-aged to older dogs, with median ages at diagnosis varying by breed and by form of the disease. It is not typically a disease of puppies or young adults, which is part of why it is hard to breed against: affected dogs can produce litters before anything is visible.
Should I give my dog joint supplements to prevent it?
Treat that as a veterinary conversation rather than a prevention plan. The research finding concerns dogs already being treated for joint disease, and it describes an association. What is well supported is keeping your dog lean, protecting joints during growth, and having limps assessed early rather than waited out.
Why breed with Bernese lineage at all?
Because the temperament and the presence of these dogs is what families are asking for, and because the alternative to doing it carefully is other people doing it carelessly. Our position is that the lineage is worth working with when the parents are screened, the pairings are outcrossed, and families are told the truth about what comes with it.
What do you do with what families report back?
We ask families to tell us about diagnoses, and we record what comes in so that we can track patterns across our lines over time rather than relying on memory. That record is incomplete by its nature, because it depends on families choosing to tell us, and it still beats having no record at all.
A note on what this is
This is educational information from a breeding program, not veterinary advice. It does not diagnose, and it is not a substitute for examination by your veterinarian. If something in your dog's health concerns you, call your veterinarian rather than acting on anything you read here.
Keep reading
- Bernedoodle health and lifespan: what the evidence supports
- The Bernese Mountain Dog: the breed behind the cross
- The quiet luxury of genetic diversity
- What health testing should a dog breeder actually do
- Canine lymphoma: a guide for owners and breeders
- Mast cell tumors in dogs
- Growing pains in larger doodles: understanding panosteitis
- The Stokeshire Method
Sources
- Moore PF. (2014). "A review of histiocytic diseases of dogs and cats." Veterinary Pathology, 51(1), 167 to 184. doi.org
- Affolter VK, Moore PF. (2002). "Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs." Veterinary Pathology, 39(1), 74 to 83. doi.org
- Fulmer AK, Mauldin GE. (2007). "Canine histiocytic neoplasia: an overview." The Canadian Veterinary Journal, 48(10), 1041 to 1050. pmc.ncbi.nlm.nih.gov
- Dobson JM. (2013). "Breed-predispositions to cancer in pedigree dogs." ISRN Veterinary Science, 2013:941275. doi.org
- Fujiwara-Igarashi A, Fujimori T, Oka M, et al. (2014). "Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan." Journal of Veterinary Medical Science, 76(5), 677 to 684. pmc.ncbi.nlm.nih.gov
- Hedan B, Rault M, Abadie J, et al. (2021). "Identification of common predisposing loci to hematopoietic cancers in four dog breeds." PLOS Genetics, 17(4):e1009395. doi.org
- Abadie J, Hedan B, Cadieu E, et al. (2009). "Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed." Journal of Heredity, 100(Suppl 1), S19 to S27. pmc.ncbi.nlm.nih.gov
- Nielsen L, Andreasen SN, Andersen SD, Kristensen AT. (2010). "Malignant histiocytosis and other causes of death in Bernese mountain dogs in Denmark." Veterinary Record, 166(7), 199 to 202. doi.org
- Erich SA, Rutteman GR, Teske E. (2013). "Causes of death and the impact of histiocytic sarcoma on the life expectancy of the Dutch population of Bernese mountain dogs and Flat-coated retrievers." The Veterinary Journal, 198(3), 678 to 683. doi.org
- Klopfenstein M, Howard J, Rossetti M, Geissbuhler U. (2016). "Life expectancy and causes of death in Bernese mountain dogs in Switzerland." BMC Veterinary Research, 12:153. doi.org
- van Kuijk L, van Ginkel K, de Vos JP, et al. (2013). "Peri-articular histiocytic sarcoma and previous joint disease in Bernese mountain dogs." Journal of Veterinary Internal Medicine, 27(2), 293 to 299. doi.org
- Manor EK, Craig LE, Sun X, Cannon CM. (2018). "Prior joint disease is associated with increased risk of periarticular histiocytic sarcoma in dogs." Veterinary and Comparative Oncology, 16(1), E83 to E88. doi.org
- Ruple A, Morley PS. (2016). "Risk factors associated with development of histiocytic sarcoma in Bernese mountain dogs." Journal of Veterinary Internal Medicine, 30(4), 1197 to 1203. doi.org
- Thaiwong T, Sirivisoot S, Takada M, et al. (2025). "Transcriptome analysis of canine histiocytic sarcoma tumors and cell lines reveals multiple targets for therapy." Cancers, 17(6):954. mdpi.com
- Bernese Mountain Dog Club of America. "Antagene Histio Pre-Test." bmdca.org
A family-run breeding and development program in Medford, Wisconsin, established 2020. Our program is structured around temperament stability, genetic diversity, and COI analysis. Licensed by the Wisconsin Department of Agriculture, Trade and Consumer Protection, license #514401-DS. James on LinkedIn
Questions about this article are welcome at hello@wisconsindesignerdoodles.com